Blog
RSS FeedPosted by Michael Wonder on 21 Apr 2022
Hansa Biopharma granted added benefit ASMR 3 by French Transparency Commission for Idefirix (imlifidase) as desensitisation treatment for highly sensitised kidney transplant patients
20 April 2022 - The opinion by the Transparency Commission follows after Idefirix was granted a funded Early Access Program by ...
Posted by Michael Wonder on 13 Apr 2022
Europe’s new HTA system spurs more debate, concern
12 April 2022 - Fresh round of discussions around health technology assessment. ...
Posted by Michael Wonder on 30 Mar 2022
Cystic fibrosis: early access granted to the Kaftrio/Kalydeco combination
29 March 2022 - The High Authority for Health has authorised early access to a first treatment for children aged 6 ...
Posted by Michael Wonder on 19 Mar 2022
COVID-19: a second booster reserved for those most at risk
18 March 2022 - While the COVID-19 epidemic seems to be on the rise again after a few weeks of decline, ...
Posted by Michael Wonder on 22 Jan 2022
COVID-19: early access granted to Paxlovid as a curative treatment
21 January 2022 - In the context of very high circulation of SARS-CoV-2, the High Authority for Health (HAS) and the ...
Posted by Michael Wonder on 09 Aug 2021
Competition from biosimilars drives price reductions for biologics in the French single payer health system
6 August 2021 - France has a single payer health insurance system that has the authority to impose pharmaceutical price reductions ...
Posted by Michael Wonder on 13 Apr 2021
Europe tries to lower drug prices with small doses of transparency
13 April 2021 - For countries in Europe, negotiating a deal with a pharma company over drug prices is the ...
Posted by Michael Wonder on 24 Mar 2021
The contribution of French patient and consumer groups to health technology assessments over a 2 year period: an observational retrospective study
22 March 2021 - In 2017, The French National Authority for Health created an open, online, systematic contribution process to enable ...
Posted by Michael Wonder on 15 Dec 2020
Vaccination strategy against SARS-Cov-2
15 December 2020 - Intermediate recommendations on the methods of implementing vaccination. ...
Posted by Michael Wonder on 04 Dec 2020
COVID-19 vaccine will be free of charge, 1 million inoculations set for January, French PM say
3 December 2020 - After the vaccination of an initial 1 million people in January an additional 14 million at ...
Posted by Michael Wonder on 17 Sep 2020
Transparency Commission publishes its opinion on Veklury
17 September 2020 - Gilead withdrew its request for the reimbursement of remdesivir in France on 31 August 2020. ...
Posted by Michael Wonder on 22 Apr 2020
Managed Entry Agreements: policy analysis from the European perspective
21 April 2020 - This article begins with a short review of the existing taxonomy of managed entry agreements and includes ...
Posted by Michael Wonder on 17 Jan 2020
France removes state funding for dementia drugs
17 January 2020 - The first country in Europe to act on concerns over limited effectiveness. ...
Posted by Michael Wonder on 03 Dec 2019
Could or should we use MCDA in the French HTA process?
3 December 2019 - Over the last decade, an increasing literature has been highlighting the benefits of introducing multi-criteria decision analysis ...
Posted by Michael Wonder on 20 Nov 2019
French Authorities approve national reimbursement of Orkambi (lumacaftor/ivacaftor) for eligible people ages two and older with cystic fibrosis
20 November 2019 - Vertex Pharmaceuticals today announced that the French Authorities (Comité économique des produits de santé, or CEPS) ...